PMID- 19005465
OWN - NLM
STAT- MEDLINE
DCOM- 20090507
LR  - 20220317
IS  - 1740-634X (Electronic)
IS  - 0893-133X (Linking)
VI  - 34
IP  - 5
DP  - 2009 Apr
TI  - A randomized, placebo-controlled study of memantine as adjunctive treatment in 
      patients with schizophrenia.
PG  - 1322-9
LID - 10.1038/npp.2008.200 [doi]
AB  - Memantine, an uncompetitive antagonist of glutamate receptors of the 
      N-methyl-D-aspartate type is approved for the treatment of moderate to severe 
      Alzheimer's disease. A growing body of evidence supports a link between the 
      glutamatergic neurotransmission and schizophrenia. The purpose of this study 
      (MEM-MD-29) was to examine the efficacy and safety of memantine as an adjunctive 
      treatment to atypical antipsychotics in patients with persistent residual 
      psychopathology of schizophrenia. In this double-blind, placebo-controlled study, 
      participants were assigned to receive 20 mg/day memantine (n=70) or placebo 
      (n=68), in addition to continuing treatment with atypical antipsychotics, for 8 
      weeks. The primary efficacy measure was the total score on the Positive and 
      Negative Symptom Scale (PANSS). Secondary measures were positive and negative 
      PANSS scores, PANSS responders, Calgary Depression Scale for Schizophrenia 
      (CDSS), Clinical Global Impression of Severity (CGI-S), Clinical Global 
      Impression of Improvement (CGI-I), and Brief Assessment of Cognition in 
      Schizophrenia (BACS). Missing data were imputed using the last observation 
      carried forward (LOCF) approach. Safety was assessed by means of physical 
      examination, clinical laboratory evaluation, recording of adverse events (AEs), 
      and measures of extrapyramidal symptoms. At end point, total PANSS scores did not 
      differ between the memantine and the placebo group (p=0.570, LOCF). A similar 
      outcome was observed for all secondary measures. The frequency of serious AEs in 
      the memantine vs placebo group was 8.7 vs 6.0%; treatment discontinuations 
      because of AEs occurred in 11.6 and 3.0% of patients in these groups, 
      respectively. Memantine showed no efficacy as an adjunctive therapy in 
      schizophrenia patients with residual psychopathology and was associated with a 
      higher incidence of AEs than placebo.
FAU - Lieberman, Jeffrey A
AU  - Lieberman JA
AD  - Department of Psychiatry, Columbia University, College of Physicians and 
      Surgeons, New York, NY 10032, USA. jlieberman@columbia.edu
FAU - Papadakis, Kelly
AU  - Papadakis K
FAU - Csernansky, John
AU  - Csernansky J
FAU - Litman, Robert
AU  - Litman R
FAU - Volavka, Jan
AU  - Volavka J
FAU - Jia, Xinwei Daniel
AU  - Jia XD
FAU - Gage, Allyson
AU  - Gage A
CN  - MEM-MD-29 Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20081112
PL  - England
TA  - Neuropsychopharmacology
JT  - Neuropsychopharmacology : official publication of the American College of 
      Neuropsychopharmacology
JID - 8904907
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - W8O17SJF3T (Memantine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antipsychotic Agents/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Excitatory Amino Acid Antagonists/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Memantine/*therapeutic use
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales
MH  - Schizophrenia/*drug therapy
MH  - Treatment Outcome
MH  - Young Adult
FIR - Green, Alan
IR  - Green A
FIR - Csernansky, John
IR  - Csernansky J
FIR - Jin, Hua
IR  - Jin H
FIR - McEvoy, Joseph
IR  - McEvoy J
FIR - Miller, Alexander
IR  - Miller A
FIR - Miller, Del
IR  - Miller D
FIR - Nasrallah, Henry
IR  - Nasrallah H
FIR - Pucilowski, Olgierd
IR  - Pucilowski O
FIR - Steinbook, Richard
IR  - Steinbook R
FIR - Volavka, Jan
IR  - Volavka J
FIR - Bari, Mohammed A
IR  - Bari MA
FIR - Knesevich, Mary Ann
IR  - Knesevich MA
FIR - Litman, Robert E
IR  - Litman RE
EDAT- 2008/11/14 09:00
MHDA- 2009/05/08 09:00
CRDT- 2008/11/14 09:00
PHST- 2008/11/14 09:00 [pubmed]
PHST- 2009/05/08 09:00 [medline]
PHST- 2008/11/14 09:00 [entrez]
AID - npp2008200 [pii]
AID - 10.1038/npp.2008.200 [doi]
PST - ppublish
SO  - Neuropsychopharmacology. 2009 Apr;34(5):1322-9. doi: 10.1038/npp.2008.200. Epub 
      2008 Nov 12.